Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.

Revenue
+8.28%
EPS
+36.7%
Free cash flow
+19.1%
Total debt
+44.9%

Quarter to September 2026, against a year earlier

229.63 3.29 +1.45%
Market cap
$159.2B
P/E
37.0×
Fwd P/E
36.9×
Dividend yield
0.67%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

45.15 36.53 33.71 36.20
P/S ratio
6.64 5.42 5.35 6.09
P/FCF ratio
30.82 25.24 24.48 27.11
P/Operating CF
77.07 101.53 87.58 82.68
P/B ratio
3.11 2.53 2.55 2.91
EV/Sales
7.20 5.90 6.18 6.82
EV/EBITDA
24.79 20.17 20.14 21.89
EV/FCF
33.43 27.47 28.26 30.37
Current Ratio
1.87 1.87 1.65 1.63
Net Debt/EBITDA
6.49 6.02 11.35 9.12
Debt/Equity
0.35 0.33 0.48 0.45
Earnings Yield
2.21% 2.74% 2.97% 2.76%
Free Cash Flow Yield
3.24% 3.96% 4.09% 3.69%
Free Cash Flow per Share
2.48 1.53 1.79 2.32
Book value per Share
73.72 74.81 74.57 76.20
Free Cash Flow
1,769.00 1,085.00 1,265.00 1,632.00
EV/EBIT
37.73 30.69 30.26 33.47
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026